These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 23807172

  • 41. Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
    Jiang X, Feng K, Zhang Y, Li Z, Zhou F, Dou H, Wang T.
    Oncotarget; 2015 May 20; 6(14):12340-56. PubMed ID: 25895026
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J.
    PLoS One; 2017 May 20; 12(9):e0185088. PubMed ID: 28934275
    [Abstract] [Full Text] [Related]

  • 48. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
    Kim MJ, Choi YK, Park SY, Jang SY, Lee JY, Ham HJ, Kim BG, Jeon HJ, Kim JH, Kim JG, Lee IK, Park KG.
    Mol Cancer Res; 2017 Sep 20; 15(9):1230-1242. PubMed ID: 28584024
    [Abstract] [Full Text] [Related]

  • 49. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
    Zhang QB, Sun HC, Zhang KZ, Jia QA, Bu Y, Wang M, Chai ZT, Zhang QB, Wang WQ, Kong LQ, Zhu XD, Lu L, Wu WZ, Wang L, Tang ZY.
    PLoS One; 2013 Sep 20; 8(2):e55945. PubMed ID: 23409093
    [Abstract] [Full Text] [Related]

  • 50. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
    Ishijima N, Kanki K, Shimizu H, Shiota G.
    Cancer Sci; 2015 May 20; 106(5):567-75. PubMed ID: 25683251
    [Abstract] [Full Text] [Related]

  • 51. Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma.
    Cheng Y, Luo R, Zheng H, Wang B, Liu Y, Liu D, Chen J, Xu W, Li A, Zhu Y.
    Oncotarget; 2017 Apr 04; 8(14):23265-23276. PubMed ID: 28423574
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
    Hu B, Sun D, Sun C, Sun YF, Sun HX, Zhu QF, Yang XR, Gao YB, Tang WG, Fan J, Maitra A, Anders RA, Xu Y.
    Biochem Biophys Res Commun; 2015 Dec 25; 468(4):525-32. PubMed ID: 26482853
    [Abstract] [Full Text] [Related]

  • 55. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C.
    Leukemia; 2013 Aug 25; 27(8):1677-87. PubMed ID: 23360848
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.
    Coriat R, Nicco C, Chéreau C, Mir O, Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F, Batteux F.
    Mol Cancer Ther; 2012 Oct 25; 11(10):2284-93. PubMed ID: 22902857
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY, Tai WT, Hsieh CY, Hsu WM, Lai YJ, Chen LJ, Shiau CW, Chen KF.
    Cancer Lett; 2014 Jul 28; 349(2):136-43. PubMed ID: 24735751
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.